

# Pathway to Advancing Care:

Evolving treatment strategies for  
HR-positive mBC



**DATE**  
Friday 6<sup>th</sup>  
December 2024



**TIME**  
15:30 - 16:30 SGT



**LOCATION**  
Hall 401, Level 4,  
Suntec Singapore Convention  
& Exhibition Centre, Singapore

## JOIN OUR EXPERT PANEL OF SPEAKERS AS THEY:

- Review the current HR-positive mBC treatment landscape, remaining unmet needs, and strategies to harness available biomarkers to optimise clinical management
- Discuss the latest advances in the HR-positive treatment landscape, focusing on emerging therapies
- Share best practices to enhance patient management through case-based discussions

## AGENDA



**15:30 – 15:35**

### The current HR-positive mBC treatment paradigm

Prof. Rebecca Dent (Chair), National Cancer Center, Singapore



**15:35 – 15:50**

### Exploring biomarker-driven approaches in HR-positive mBC

Prof. Hope S. Rugo, University of California San Francisco, USA



**15:50 – 16:00**

### Navigating new frontiers post-ET with ADCs

Dr Shaheenah Dawood, Mediclinic City Hospital Dubai, UAE



**16:00 – 16:30**

### Advancing patient care: Optimising treatment strategies

All faculty



### Summary and closing remarks

Prof. Rebecca Dent (Chair), National Cancer Center, Singapore

This is a non-promotional medical education meeting organised and funded by AstraZeneca for healthcare professionals only. AstraZeneca molecules will be discussed at this meeting.

During this meeting, data may refer to medicines or indications under investigation or that may not be approved in your country. The information should under no circumstances be regarded as a recommendation for use of the medicine or indication. Please consult your local prescribing information.

AstraZeneca Singapore Pte Ltd  
10 Kallang Avenue #12-10 Aperia Tower 2, Singapore 339510  
Telephone: +65 68124700  
Fax: +65 63853050

For adverse event reporting and/or request for Medical Information, please visit [contactazmedical.astrazeneca.com](https://contactazmedical.astrazeneca.com)

JBN: SG-8435 | DOP: October 2024